The board of directors of the company has its meeting held today inter alia considered and approved financial results for the quarter and financial year ended on 31st March, 2025 along ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma Ltd, a Rajkot-based pharmaceutical bulk drugs maker, reported FY25 revenue of Rs. 28.2 crores, up sharply from Rs. 11.05 crores in FY24 — a jump of roughly 155%. Despite this strong top-line growth, the company posted a net loss of Rs. 2.09 crores for the full year (vs Rs. 5.75 crores loss in FY24), and a Q4 loss of Rs. 1.49 crores. Shareholder equity turned negative at Rs. (1.99 crores) from a small positive Rs. 0.10 crores earlier, meaning accumulated losses have wiped out invested capital. Operating cash flow stayed negative at Rs. (0.66 crores) and the company raised Rs. 1.4 crores of fresh borrowings to fund operations. Q4 carried an exceptional loss of Rs. 1.07 crores related to fire damage at the manufacturing plant. The auditor's report contains two qualifications: Rs. 3.69 crores of fire-related expenditure sits in current assets without a formal insurance claim, and a Rs. 40 lakh mutual fund investment is held in the MD's name, violating Section 187 of the Companies Act.
The big revenue jump is encouraging, but the company remains loss-making, has negative book value, and burning cash — red flags for a going concern. The qualified audit report (contradicting the company's own note claiming an 'unqualified' opinion) and the unresolved insurance claim add further uncertainty. Retail investors should treat this as a high-risk, speculative situation.